New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Core Insights - Myriad Genetics announced a meta-analysis showing that the GeneSight Psychotropic test significantly improves response and remission rates in patients with major depressive disorder (MDD) compared to treatment as usual (TAU) [1][2][3] Study Details - The meta-analysis included six prospective controlled studies with a total of 3,532 adults with MDD who had experienced at least one treatment failure [4] - Response was defined as a 50% or greater improvement in depression scores, while remission was defined as a score of seven or less on the Hamilton Depression Rating Scale (HAM-D17) or five or less on the Patient Health Questionnaire (PHQ-9) [4] GeneSight Test Overview - The GeneSight Psychotropic test analyzes how a patient's genes may affect their response to 64 commonly prescribed psychiatric medications, aiming to reduce the trial-and-error process in medication management [5] Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [6]